BAY 12-9566

BAY 12-9566

A novel inhibitor of matrix metalloproteinases with antiangiogenic activity, which made it to phase-III trials for managing advanced pancreatic cancer but proved inferior to gemcitabine (4-month survival vs 7-month survival, respectively), the agent against which is was being compared, and subsequently has been abandoned.
References in periodicals archive ?
24 /PRNewswire/ -- Bayer Corporation, Pharmaceutical Division announced today that it has halted all clinical trials of its MMPI (matrix metalloproteinase inhibitor) BAY 12-9566 in cancer and osteoarthritis.
Bayer decided to halt all these trials with BAY 12-9566 as a precautionary measure.
MMPI's like BAY 12-9566 are designed to interfere with this process.